315 results
Page 5 of 16
8-K
EX-99.1
4jcfqovi
9 Apr 19
Entry into a Material Definitive Agreement
4:43pm
8-K
EX-99.2
7txzp
9 Apr 19
Entry into a Material Definitive Agreement
4:43pm
PRER14A
koai73ih5ih4ibwtlii
18 Mar 19
Preliminary revised proxy
5:24pm
PRE 14A
fzdpx
11 Mar 19
Preliminary proxy
5:07pm
8-K
EX-99.1
3hsz 0bikmk7v7
7 Feb 19
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Recent Period Activity
4:15pm
8-K
EX-99.1
wt80j
15 Jan 19
Entry into a Material Definitive Agreement
5:19pm
424B5
0l6xyl7mhm
15 Jan 19
Prospectus supplement for primary offering
5:14pm
424B5
22em 8jvl9plv08det4y
14 Jan 19
Prospectus supplement for primary offering
4:41pm
8-K
EX-99.1
ov3 ucmtnyj2lv1z
7 Jan 19
Results of Operations and Financial Condition
8:11am
8-K
EX-99.1
7249dye5docp pp7uuxu
7 Nov 18
Alnylam Pharmaceuticals Reports Third Quarter 2018 Financial Results and Highlights Recent Period Activity
8:16am
8-K
EX-99.1
h9bt38z 3jt
10 Aug 18
ONPATTROâ„¢ (patisiran) for the Treatment of the Polyneuropathy of Hereditary
3:45pm
8-K
EX-99.1
8ttttw19i4ryqo0vyxb
2 Aug 18
Alnylam Pharmaceuticals Reports Second Quarter 2018 Financial Results and Highlights Recent Period Activity
8:15am